Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | CBS | P35520 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220626 | 0.86 | EPHX2 (0.39) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL7268276 | 0.84 | SMN1; SMN2 (0.38) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL27386798 | 0.84 | SMN1; SMN2 (0.38) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL29223001 | 0.83 | EPHX2 (0.37) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL19772732 | 0.80 | EPHX2 (0.41) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL25041340 | 0.78 | SMN1; SMN2 (0.35) | TSHRKDM4EALDH1A1 | |
| SCHEMBL26288350 | 0.77 | SMN1; SMN2 (0.34) | EPHX2CYP2C19TSHRCTHCBS | |
| SCHEMBL17011631 | 0.76 | — | — | |
| SCHEMBL17833053 | 0.75 | BLM (0.35) | EPHX2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL18251468 | 0.75 | EPHX2 (0.42) | EPHX2CYP2C19TSHRCYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627772-B2 | Preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | THE DOW CHEMICAL COMPANY | 2003-09-30 | — | — | US | claimed |
| US-20020147360-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | ATHEY PHILLIP S (US) | 2002-10-10 | — | — | US | claimed |
| US-20020010367-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | ATHEY PHILLIP S (US) | 2002-01-24 | — | — | US | claimed |
| WO-2000076959-A2 | INTERMEDIATES FOR THE PREPARATION OF (N)-[2-(CARBOXYMETHOXY) ETHYL]-(N)-(CARBOXYMETHYL) GLYCINE | THE DOW CHEMICAL COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-6627772-B2 | Preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | THE DOW CHEMICAL COMPANY | 2003-09-30 | — | — | US | disclosed |
| US-20020147360-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | ATHEY PHILLIP S (US) | 2002-10-10 | — | — | US | disclosed |
| US-6392095-B2 | HYDROLYSIS; HARD SURFACE CLEANING COMPOUNDS | THE DOW CHEMICAL COMPANY | 2002-05-21 | — | — | US | disclosed |
| US-20020010367-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | ATHEY PHILLIP S (US) | 2002-01-24 | — | — | US | disclosed |
| US-6288263-B1 | AMINO CARBOXY ETHERS AND SALTS | THE DOW CHEMICAL COMPANY | 2001-09-11 | — | — | US | disclosed |
| WO-2000076959-A2 | INTERMEDIATES FOR THE PREPARATION OF (N)-[2-(CARBOXYMETHOXY) ETHYL]-(N)-(CARBOXYMETHYL) GLYCINE | THE DOW CHEMICAL COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010367-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | GNMT, GRM1, CPN1 | EPHX2 602/4885CYP2C19 1947/4885TSHR 3882/4885 |
| US-20020147360-A1 | Intermediates for the preparation of N-[2-(carboxymethoxy) ethyl]-N-(carboxymethyl) glycine | GNMT, GRM1, CPN1 | EPHX2 602/4885CYP2C19 1947/4885TSHR 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.